# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Klotho Neurosciences (NASDAQ:KLTO) reported quarterly losses of $(0.12) per share. This is a 300 percent decrease over losses o...
Key partnerships, regulatory progress, manufacturing advancements, along with significant capital infusion accelerate the deve...
Company to Pursue Technologies to Improve Muscle Strength, Bone Health, and Other Longevity IndicatorsNEW YORK, July 24, 2025 /...
-SEC Filing